To continue reading this content, please enable JavaScript in your browser settings and refresh this page. In April 2021, the FDA approved the 100th monoclonal ...

Monoclonal antibodies are widely used to treat diseases ranging from cancer to autoimmune disorders. The safety and efficacy of these biologic drugs depend on maintaining their correct ...

In the last few years, multispecific antibodies, such as bispecific, trispecific, and tetraspecific antibodies, have become the breakthrough stars in antibody therapeutics. Compared with conventional ...

In the not-too-distant past, scientists in biological research found themselves burdened with the time-consuming tasks of developing, purifying, and characterizing the antibodies they worked with in ...

Antibodies are small proteins that are secreted by specialized cells to target and neutralize pathogens. The “Y” shaped structure is crucial for active immunity and work by binding and tagging ...

Monoclonal antibodies have become one of the most established and clinically successful therapeutic modalities, supported by ...

Download this handbook to learn more about the capabilities of mass photometry for evaluating antibody aggregation and binding. When experiments refuse to cooperate, you try again and again. For ...

iBio (IBIO) in collaboration with AstralBio announced the development of an antibody that inhibits the function of Activin E, a promising therapeutic target for cardiometabolic disorders and obesity ...

Explore the latest developments showcased at World ADC, highlighting smarter payloads and precise targeting in drug discovery.

This presentation looks at the dynamic landscape of therapeutic antibody development, focusing on next-generation immuno-oncology therapeutics that target checkpoint inhibitors and incorporate the ...